Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same

1 . Acetylsalicylic acid Form II, wherein said acetylsalicylic acid Form II exhibits crystal parameters that are approximately equal to the following:

Monoclinic, P2 1 /c; a=12.095(7) Å, b=6.491(4) Å, c=11.323(6) Å; β=111.509(9)°: V=827.1(8) Å 3 ; Z=4.

2 . (canceled)

3 . The acetylsalicylic acid Form II of claim 1 , wherein said acetylsalicylic acid Form II exhibits a melting point at about 128-130 degrees C.

4 . The acetylsalicylic acid Form II of claim 1 , wherein said acetylsalicylic acid Form II exhibits an IR spectrum comprising peaks selected from the group consisting of:

(i) 1667, 1455, 1288, and 1187 cm −1 ;

(ii) 1087, 1009, 916, and 752 cm −1 ; and

(iii) 1667, 1288, 1009, and 916 cm −1 .

5 . A method of making acetylsalicylic acid Form II, comprising:

(a) mixing acetylsalicylic acid with levetiracetam and an appropriate solvent; and

(b) crystallizing acetylsalicylic acid under conditions which lead to the formation of Form II according to claim 1 .

6 . A pharmaceutical dosage form comprising a therapeutically effective amount of said acetylsalicylic acid Form II of claim 1 .

7 . A pharmaceutical dosage form comprising a pharmaceutically acceptable carrier, diluent, or excipient and a therapeutically effective amount of said acetylsalicylic acid Form II of claim 1 .

8 . A method of treating a mammal with a condition selected from the group consisting of: pain, headache pain, arthritis pain, fever, pre-eclampsia, heart attack, and predisposition of heart attack, which comprises administering to the mammal a therapeutically effective amount of acetylsalicylic acid Form II according to claim 1 .